Selecting β-thalassemia Patients for Gene Therapy: A Decision-making Algorithm.

Area of Science:

• Hematology
• Medical Genetics
• Clinical Decision-Making

Background:

• Gene therapy (GT) presents a new treatment paradigm for transfusion-dependent beta-thalassemia (TDT).
• Allogeneic hematopoietic stem-cell transplantation (HSCT) is an established curative option for TDT.
• Establishing priority indications for GT is crucial due to its current limitations in availability, cost, and resources.

Purpose of the Study:

• To develop a priority decision-making algorithm for identifying TDT patients suitable for gene therapy (GT).
• To guide the rational and progressive adoption of innovative GT treatments in clinical practice.
• To leverage experience from allogeneic HSCT as a predictive model for GT indications.

Main Methods:

• Expert opinion developed by the Italian Society of Thalassemias and Hemoglobinopathies (SITE).
• Reviewed and adopted by the European Hematology Association (EHA) Scientific Working Group on Red Cells and Iron.
• Algorithm development based on evidence, consensus, and predictive modeling using HSCT outcomes.

Main Results:

• The algorithm considers various clinical scenarios and their impact on treatment outcomes.
• Optimal pre-transplant transfusion and chelation therapy are key predictors of successful HSCT outcomes.
• The algorithm aims to prioritize GT for TDT patients based on evidence and clinical condition.

Conclusions:

• This expert opinion provides dynamic, updatable, priority-based indications for physicians managing TDT patients.
• The algorithm serves as a guide for the rational and progressive use of gene therapy in TDT.
• Physicians should consider patient clinical condition and prior therapies when evaluating GT suitability.